Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management

Acta Oncologica

Volumn 28, Issue 3, 1989, Pages 389-402

  Vinik, A I ^a   Thompson, N ^a   Eckhauser, F ^a   Moattari, A R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Carcinoid syndrome; Clinical features; Somatostatin analogue

Indexed keywords

OCTREOTIDE;

CARCINOID SYNDROME; COMPUTER ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

HUMAN; MALIGNANT CARCINOID SYNDROME; OCTREOTIDE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024319702     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841868909111212     Document Type: Article

References (78)

1. Neuroendocrine tumors. A European view
2. Unusual cyanosis in a boy with congenital pulmonary stenosis and tricuspid insufficiency
3. The malignant carcinoid syndrome
4. Morphological and functional classification of endocrine cells and related growths in the gastrointestinal tract
5. Gastroenteropancreatic endocrine tumors
6. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report
7. Immunohistochemical localization of neuron-specific enolase in gastroentero-pancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase
8. Distinguishing features of idiopathic flushing and carcinoid syndrome
9. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man
10. Metaidobenzylguanidine as an index of the adrenergic nervous system integrity and function
11. lodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors
12. Substance P in the localization of a carcinoid tumor
13. Carcinoid tumors of the small intestine
14. Urinary serotonin in the diagnosis of carcinoid tumor
15. Treatment of malabsorption and diarrhea of carcinoid syndrome with methysergide
16. Prostaglandin in amine-peptide-secreting tumors
17. Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid
18. Evidence for the release of bradykinin in the carcinoid syndrome
19. Determination of 5-hydroxytryptamine, 5 hydrosyindolacetic acid and histamine in thirty-three cases of carcinoid tumor (argentaffinoma)
20. Substance P and enteroglucagon-like immunoreactivity in argentaffin and argyrophil mid gut carcinoid tumors
21. Flushing in the carcinoid syndrome and plasma kallikrein
22. Determination of 5-hydroxytryptamine, 5-hydroxy-indoleacetic acid and histamine in 33 cases of carcinoid (argentaffinoma)
23. Increased dopamine production in patients with carcinoid tumors
24. Neuropeptide K: A major tachykinin in plasma and tumor tissues from carcinoid patients
25. Unusual gastroenteropancreatic tumors and their hormones
26. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors
27. Gastrointestinal hormones in clinical medicine
28. The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay
29. A rapid, sensitive method for direct estimation of serotonin in whole blood
30. The concentration of serotonin in normal human serum as determined by an improved method
31. The determination of serotonin (5-hydroxytryptamine) in human blood
32. The use of somatostatin analogue in the management of the carcinoid syndrome
33. Carcinoid syndrome
34. Substance P in ovarian carcinoid
35. The pentagastrin test in the diagnosis of the carcinoid syndrome
36. A new provocative test for the diagnosis of carcinoid syndrome
37. Circulating tachykinins (substance P, neurokinin A and neuropeptide K) and the carcinoid flush
38. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush
39. Menopausal flushes: A neuroendocrine link with pulsatile leuteinizing hormone secretion
40. Pathophysiology of hot flushes
41. The effect of clonidine on vascular reactivity of angiotensin, noradrenaline and vasopresin in conscious rats
42. Physiological aspects of menopausal hot flush
43. Sulfamides hy-poglycemiants et effet antabuse
44. Inhibitory influence of ethanol on serotonin metabolism
45. Alcohol sensitivity in diabetics receiving chlorpropamide
46. The high familial prevalence of neurocirculatory asthenia
47. Age of onset of phobic disorders: A reevaluation
48. Human calcitonin: immunologic assay, cytologic localization and studies on medullary thyroid carcinoma
49. Katacalcin: a new plasma calcium-lowering hormone
50. Dopa decarboxylase in medullary carcinoma of the thyroid
51. Cushing's syndrome caused by ACTH and calcitonin-secreting medullary carcinoma of the thyroid
52. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma
53. Serotin (5-hydroxytryptamine) in medullary thyroid carcinoma with or without pheochromocytoma
54. Cerebellar tumours presenting with clinical features of phaeochromocytoma
55. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy
56. The role of hepatic arterial embolization in the carcinoid syndrome
57. Treatment of the carcinoid tumor and the malignant carcinoid syndrome
58. Carcinoid crisis: rapid reversal of the life threatening hypotension with a somatostatin analogue
59. The use of a somatostatin analogue in the management of the flushing syndrome
60. Somatostatin analogue (SMS 201–995) in the management of gastroenteropancreatic tumors and diarrhea syndromes
61. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man
62. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action
63. The carcinoid flush provocation by pentagastrin and inhibition by somatostatin
64. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue
65. Short-term administration of somatostatin analogue SMS 20–1995 in patients with carcinoid tumors
66. Pancreatic cholera syndrome-effect of a synthetic somatostatin analogue on intestinal water and ion transport
67. Lankisch Somatostatin and the gastrointestinal tract
68. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201–995
69. The influence of somatostatin on the absorption of triglycerides in partially gastrectomized subjects
70. Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: symtomatic and peptide responses
71. Myelopathy secondary to metastatic carcinoid tumors
72. Carcinoid myopathy and treatment with cyproheptadine (periactin)
73. Neuromyopathy associated with a malignant carcinoid tumor
74. Myasthenia gravis associated with a hormone producing malignant carcinoid tumor
75. Morphologic changes in skeletal muscle induced by serotonin treatment, a light and electron miscroscopy study
76. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases